Clinical trial
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic…
NCT00072475 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00072475 |
|---|---|
| Title | Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes |
| Official title | A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS) |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms |
| Intervention type | Drug |
| Interventions | vatalanib |
| Enrollment | 155 |
| Start date | Dec 1, 2003 |
| Primary completion | Nov 1, 2008 |
| Completion | Jun 1, 2014 |
| First posted | Nov 6, 2003 |
| Last update posted | Aug 1, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: